Skip to main content
OpenTrials
Completed

NCT Number: NCT04492878

Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment

The proposed study is a prospective, open-label, unicentric, phase IV clinical trial.

This study is design to find new efficacy biomarkers for IKERVIS® (1mg/mL ciclosporin) eye drops after 1 and 3 month after initiation of therapy. Additionally, this study intends to investigate whether IKERVIS® will help patients to better overcome situations of desiccating stress by exposing them to an adverse controlled environment (ACE) and analyzing both clinical and molecular parameters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dry Eye Corneal Diseases Dry Eye Syndromes Eye Diseases Keratitis Lacrimal Apparatus Diseases Severe Keratitis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Institute of Applied Ophthalmobiology (IOBA)

Valladolid, 47011, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years.
  • Diagnosis of DED with Severe Keratitis who have not improved despite regular use of tear substitutes by an ophthalmologist, at least 2 months previously.
  • Not stable (as defined by the two items below) under at least 2 months of constant and regular use of artificial tears (at least 4 drops a day)
  • Fluorescein corneal staining ≥ 2 (Oxford scale) in both eyes.
  • DEQ-5 > 6 points
  • Use of at least 4 times daily of an ocular artificial tears.
  • Any concomitant medication that may affect DED, ocular surface condition or vision, must have a start date at least 3 months prior to baseline and dosage is not expected to change during the study.
  • Best corrected visual acuity (BCVA) of at least 0.1 logMar at 6 meters with each eye.
  • Signature of written informed consent form and data protection form.

Exclusion criteria

  • Known allergy or sensitivity to the study product(s) or its components.
  • Any ocular pathology other than DED.
  • History of severe ocular inflammation other than that due to DED or infection in the 6 previous months to the study inclusion.
  • Any ocular surgery or trauma that may affect corneal sensitivity and/or normal tear distribution in the 6 previous months or any ocular or systemic surgery or procedure planned during the study duration that may affect the study as assessed by principal investigator.
  • History of refractive surgery in the previous 18 months.
  • Contact lens use in the ONE previous month to study inclusion and during the duration of the study.
  • Use of any ocular topical medication for pathologies other than DED.
  • Use of any other ocular topical medication for DED other than artificial tears during the last ONE (steroids) or THREE months (ciclosporine, tacrolimus) .
  • Any uncontrolled severe systemic disease that may affect the eye (except for Sjögren's syndrome)
  • The start date of any systemic medication that may affect DED, ocular surface condition or vision is < 3 months prior to baseline or a change in dosage is anticipated during the study.
  • Occlusion of the lacrimal puncta either surgically or with plugs within one month prior to study, or anticipated use of the same during the study.
  • Pregnancy or breastfeeding.
  • Current enrolments in an investigational drug or device study or participation in such a study within 30 day of entry into this study at baseline.

Treatment and study plan

IKERVIS®1mg/mL

Drug

One drop of study medication once daily in each eye at bedtime during 90 days.

Primary outcomes

  1. Corneal fluoresceing staining

    Time frame: V1 (baseline) vs V2 (30 days of treatment); V1 (baseline) vs V3 (90 days of treatment); V2 (30 days of treatment) vs V3 (90 days of treatment)

    Significant reduction in corneal fluorescein staining

Secondary outcomes

  1. Response against adverse environmental conditions

    Time frame: V1 (baseline) vs V2 (30 days of treatment); V1 (baseline) vs V3 (90 days of treatment)

    Significant differences in the percentage of patients suffering a worsening in clinical signs and/or symptoms following exposure to adverse environmental conditions

  2. Molecular changes

    Time frame: V1 (baseline) vs V2 (30 days of treatment); V1 (baseline) vs V3 (90 days of treatment)

    Significant reduction in median expression of HLA-DR by conjunctival epithelial cells.

Sponsors and collaborators

Lead sponsor

Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA

Other

Collaborators

  • Santen Oy

Registry information

Official study title

A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis® on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients With Severe Keratitis Who Have Not Improved Despite Regular Use of Tear Substitutes Before and After Exposure to an Adverse Controlled Environment

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jul 30, 2020
Registry last updated
Apr 21, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.